Skip to main content

InvestorNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) Pearsanta Appoints Ernie Lee as CEO to Drive Launch of Test2Treat.me Platform

Aditxt (NASDAQ: ADTX) is a global innovation activation company focused on the discovery, development and deployment of technologies that monitor and modulate the immune system. The company today announced that it has appointed Ernie Lee to serve as the chief executive officer of its wholly owned subsidiary Pearsanta Inc. The appointment intends to accelerate the commercial launch of Test2Treat.me, an end-to-end, business-to-business (“B2B”) and direct-to-consumer (“DTC”) clinical diagnostic testing services platform for retail pharmacies, physician practices, employee benefit programs, and consumers. “Naming Ernie as CEO of Pearsanta is a crucial initial step in our plan to scale the company and capitalize on global opportunities,” said Amro Albanna, co-founder, chairman and CEO of Aditxt. “With Ernie at the helm, we believe that Test2Treat.me has the potential to quickly fill a void in the healthcare market for DTC point-of-care testing and treatment.”

To view the full press release, visit https://ibn.fm/sxpwk

About Aditxt Inc.

Aditxt is a global innovation company focused on discovering, developing and deploying technologies that monitor and modulate the immune system. The company is headquartered in Richmond, Virginia, with operations in Mountain View, California, and Melville, New York. Aditxt’s mission of “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders who inform and inspire its mission. Aditxt’s diverse innovation portfolio includes: Adimune(TM), Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity and allergies; Adivir(TM), Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta(TM), Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at their CLIA certified and CAP accredited clinical laboratory based in Richmond, Virginia. For more information, visit the company’s websites at www.Aditxt.comwww.Adimune.com and www.Pearsanta.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.